Q2 2025 earnings overview

Q2 2025 Earnings Overview

• Earnings Per Share (EPS): Reported at $2.02, significantly above the analyst consensus of approximately $0.70—beating by about $1.32 .

• Total Revenue: Came in at $611.1 million, surpassing estimates (~$533M consensus) .

• Net Product Revenues: ~$513 million for Q2, including $282 million from Elevidys sales, up ~42% year‑over‑year .

⸻

✅ Key Developments & Strategic Updates

FDA Safety & Elevidys Resumption

• In late July 2025, the FDA lifted a clinical hold and recommended resuming Elevidys shipments for ambulatory Duchenne muscular dystrophy patients. Non‑ambulatory dosing remains paused amid safety discussions and risk mitigation processes .

• Elevidys carries a new black-box liver toxicity warning following three patient deaths linked to its gene therapy vector .

Restructuring & Cost Discipline

• Sarepta is restructuring to achieve roughly $400M in annual cost savings by 2026, including a workforce reduction (~36% cut, ~500 roles) .

• $100M in savings are expected by end-2025 in line with ongoing reforms .

Pipeline Pivot

• The company is pivoting toward siRNA therapies (e.g., for FSHD, Huntington’s, DM1, SCA2), reprioritizing its early-stage pipeline over riskier AAV-based gene therapies

14K Views